Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report) traded down 0% during mid-day trading on Wednesday . The stock traded as low as $4.8942 and last traded at $4.9190. 47,127 shares traded hands during trading, an increase of 80% from the average session volume of 26,172 shares. The stock had previously closed at $4.92.
Ono Pharmaceutical Stock Performance
The company’s 50 day moving average is $5.08 and its 200-day moving average is $4.92.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty?pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co?developing and commercializing nivolumab (Opdivo), an anti–PD?1 immune checkpoint inhibitor developed in partnership with Bristol?Myers Squibb.
Recommended Stories
- Five stocks we like better than Ono Pharmaceutical
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
